IP Verse

Pharmaceutical Formulations Of A Hif Hydroxylase Inhibitor - EP3003284

The patent EP3003284 was granted to Fibrogen on Feb 12, 2020. The application was originally filed on Jun 5, 2014 under application number EP14735770A. The patent is currently recorded with a legal status of "Revoked".

EP3003284

FIBROGEN
Application Number
EP14735770A
Filing Date
Jun 5, 2014
Status
Revoked
Apr 2, 2025
Grant Date
Feb 12, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZNov 12, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSNov 11, 2020D YOUNGADMISSIBLE

Patent Citations (30) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013US29851-
DESCRIPTIONUS2003153503
DESCRIPTIONUS2003176317
DESCRIPTIONUS2004204356
DESCRIPTIONUS2004235082
DESCRIPTIONUS2005020487
DESCRIPTIONUS2006276477
DESCRIPTIONUS2007004627
DESCRIPTIONUS2007042937
DESCRIPTIONUS2007259960
DESCRIPTIONUS2007292433
DESCRIPTIONUS2007293575
DESCRIPTIONUS2010144737
DESCRIPTIONUS2011039878
DESCRIPTIONUS2011039879
DESCRIPTIONUS2011039885
DESCRIPTIONUS2011263642
DESCRIPTIONUS2012149712
DESCRIPTIONUS7323475
DESCRIPTIONWO2012097329
DESCRIPTIONWO2012097331
DESCRIPTIONWO2013070908
INTERNATIONAL-SEARCH-REPORTUS2012149712
INTERNATIONAL-SEARCH-REPORTWO2012097331
OPPOSITIONEP1944029
OPPOSITIONEP2382971
OPPOSITIONUS2009028943
OPPOSITIONUS2009099203
OPPOSITIONUS2012149712
OPPOSITIONWO2012097331

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "16 Photostabilization of Solid and Semisolid Dosaae Forms", Joseph T. Piechocki, Pharmaceutical Photostability and Stabilization Technology, Informa Healthcare, (20070000), pages 323 - 343, XP055752989-
OPPOSITION- ALLAM et al., "Review: Colorants - The Cosmetics for the Pharmaceutical Dosage Forms", Int. J. Pharm. Pharm. Sci., (20110000), vol. 3, pages 13 - 21, XP055303330-
OPPOSITION- Anonymous, "Diluents in color addictive mixtures for drug exempt from certification", Electronic Code of Federal Regulations - Listing of Color Additives in Drugs, (20120000), pages 1 - 18, XP055755500-
OPPOSITION- Anonymous, "Photostability Testing of new Active Substances and Medicinal Products", EMEA, (19980000), pages 1 - 9, XP055459430-
OPPOSITION- Anonymous, "Subpart B - drugs FD AND C Blue N0. 1", FDA - Electronic Code of Federal Regulations - Listing of Color Additives in Drugs, (20120811), pages 1 - 27, XP055755509-
OPPOSITION- "Coloring Agents", Rowe et al, Handbook of Pharmaceutical Excipients, PhP, (20090000), pages 189 - 196-
OPPOSITION- "Gelatin alternatives and additives", FRIDUM PODEZECK, PHARMACEUTICAL CAPSULES, GB, Pharmaceutical Press, (20040101), pages 64 - 66, XP009174495-
OPPOSITION- ICH Expert Working Group, "STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS Q1B", ICH - ICH HARMONISED TRIPARTITE GUIDELINE, (19961106), URL: https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf, XP055070354-
OPPOSITION- LIEBERMAN et al., LIEBERMAN et al., LIEBERMAN et al., Pharmaceutical Dosage Forms - Tablets, (19900000), vol. 3, pages 77 - 84, XP055755443-
OPPOSITION- RITSCHEL et al., "Kapitel 2", Die Tablette, (20020000), pages 184, - 185, XP055755492-
OPPOSITION- "Tablet formulation and design", Pharmaceutical Dosage Forms - Tablets, (19890000), vol. 1, pages 75 - 78, XP055315303-
OPPOSITION- THOMA et al., "Photostabilization of solid and semisolid dosage forms", Pharmaceutical Photostability and Stabilization Technology, (20070000), pages 323 - 336, XP055752989-
OPPOSITION- "Titanium Dioxide", Rowe et al, Handbook of Pharmaceutical Excipients. 6th ed., PhP, (20090000), pages 741 - 744, XP055743723-
OPPOSITION- TONNESEN, H.H., "Photodecomposition of Drugs", Encyclopedia of Pharmaceutical Technology, New York, (20070000), vol. 5, pages 2859 - 2865, XP002729748-
OPPOSITION- THOMA K et al., "Photostabilization of drugs in dosage forms without protection from packaging materials", International Journal of Pharmaceutics, (19910115), vol. 67, no. 2, pages 169 - 175, XP025557819
OPPOSITION- DESAI D.S et al., "Photostabilization of uncoated tablets of sorivudine and nifedipine by incorporation of synthetic iron oxides", International Journal of Pharmaceutics, (19940000), vol. 103, no. 1, pages 69 - 76, XP025577911

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents